# PSA-201 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/psa-201

> PSA-201, sponsored by MoonLake Immunotherapeutics (MLTX): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | PSA-201 |
| Codes | PSA-201 |
| Sponsor | MoonLake Immunotherapeutics (MLTX) https://sec-api.dev/companies/mltx/catalysts |
| Indications | [active psa](https://sec-api.dev/indications/active-psa) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Dec 2022: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: active PsA.
- First seen 2025-02-26, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001821586-25-000022): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm
- SEC Form 10-Q (accession 0001821586-25-000018): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000018/mnlk-20250630.htm
- SEC Form 10-Q (accession 0001821586-25-000011): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000011/mnlk-20250331.htm
- SEC Form 10-K (accession 0001821586-25-000006): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000006/mnlk-20241231.htm
- SEC Form 10-K (accession 0001821586-25-000006): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000006/mnlk-20241231.htm

### Dec 2022: topline data readout

- Status: completed, met. Date confidence: month. Stage: 2. Indication: active PsA.
- First seen 2025-02-26, last confirmed 2025-11-05.
- SEC Form 10-Q (accession 0001821586-25-000022): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000022/mnlk-20250930.htm
- SEC Form 10-Q (accession 0001821586-25-000018): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000018/mnlk-20250630.htm
- SEC Form 10-Q (accession 0001821586-25-000011): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000011/mnlk-20250331.htm
- SEC Form 10-K (accession 0001821586-25-000006): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000006/mnlk-20241231.htm
- SEC Form 10-K (accession 0001821586-25-000006): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50." https://www.sec.gov/Archives/edgar/data/1821586/000182158625000006/mnlk-20241231.htm

### Nov 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: active PsA.
- First seen 2026-02-25, last confirmed 2026-05-11.
- SEC Form 10-Q (accession 0001821586-26-000007): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm
- SEC Form 10-K (accession 0001821586-26-000002): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/mnlk-20251231.htm

### Nov 2023: topline data readout

- Status: completed, met. Date confidence: month. Stage: 2. Indication: active PsA.
- First seen 2026-02-25, last confirmed 2026-05-11.
- SEC Form 10-Q (accession 0001821586-26-000007): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)) and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000007/mnlk-20260331.htm
- SEC Form 10-K (accession 0001821586-26-000002): "In December 2022, we initiated a Phase 2b trial in patients with active PsA (the ARGO trial (M1095-PSA-201)), and in November 2023, we announced positive top-line results from this trial, which met its primary endpoint of American College of Rheumatology ("ACR") 50 with 46% of patients on 60mg SLK achieving such response at week 12." https://www.sec.gov/Archives/edgar/data/1821586/000182158626000002/mnlk-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/psa-201.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PSA-201 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/psa-201

```bibtex
@misc{secapidev_pdufa_psa_201_20261116,
  title        = {PSA-201 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/psa-201}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_psa_201_20261116","title":"PSA-201 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/psa-201","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
